<?xml version="1.0" encoding="UTF-8"?>
    <!DOCTYPE article PUBLIC "-//NLM/DTD JATS (Z39.96) Journal Publishing DTD v1.2 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
    <!--<?xml-stylesheet type="text/xsl" href="article.xsl">-->
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.2" xml:lang="en">
	<front>
		<journal-meta>
			<journal-id journal-id-type="issn">2303-9868</journal-id>
			<journal-id journal-id-type="eissn">2227-6017</journal-id>
			<journal-title-group>
				<journal-title>International Research Journal</journal-title>
			</journal-title-group>
			<issn pub-type="epub">2303-9868</issn>
			<publisher>
				<publisher-name>Cifra LLC</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="doi">10.60797/IRJ.2026.173.63</article-id>
			<article-categories>
				<subj-group>
					<subject>Brief communication</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Correction of the bile acid pool shift in loaches with experimental hepatopathies using sulfolithocholic acid</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author" corresp="yes">
					<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6852-3110</contrib-id>
					<contrib-id contrib-id-type="rinc">https://elibrary.ru/author_profile.asp?id=1065956</contrib-id>
					<name>
						<surname>Ponamarev</surname>
						<given-names>Vladimir Sergeevich</given-names>
					</name>
					<email>psevdopyos@mail.ru</email>
					<xref ref-type="aff" rid="aff-1">1</xref>
				</contrib>
			</contrib-group>
			<aff id="aff-1">
				<label>1</label>
				<institution>St. Petersburg State University of Veterinary Medicine</institution>
			</aff>
			<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-11-17">
				<day>17</day>
				<month>11</month>
				<year>2026</year>
			</pub-date>
			<pub-date pub-type="collection">
				<year>2026</year>
			</pub-date>
			<volume>6</volume>
			<issue>173</issue>
			<fpage>1</fpage>
			<lpage>6</lpage>
			<history>
				<date date-type="received" iso-8601-date="2026-10-05">
					<day>05</day>
					<month>10</month>
					<year>2026</year>
				</date>
				<date date-type="accepted" iso-8601-date="2026-10-23">
					<day>23</day>
					<month>10</month>
					<year>2026</year>
				</date>
			</history>
			<permissions>
				<copyright-statement>Copyright: &amp;#x00A9; 2022 The Author(s)</copyright-statement>
				<copyright-year>2022</copyright-year>
				<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
					<license-p>
						This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See 
						<uri xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</uri>
					</license-p>
					.
				</license>
			</permissions>
			<self-uri xlink:href="https://research-journal.org/archive/11-173-2026-november/10.60797/IRJ.2026.173.63"/>
			<abstract>
				<p>One of the most informative but still insufficiently studied markers of the hepatobiliary system in fish is the bile acid profile. In healthy fish, the bile acid pool is maintained by a balanced ratio of primary and secondary bile acids. Under hepatic pathology, this balance shifts toward more hydrophobic and cytotoxic fractions, which aggravates hepatocyte damage and supports a vicious circle. In the present study, the possibility of correcting the bile acid pool shift in common loach (Misgurnus fossilis) with experimental hepatopathies was assessed using exogenous sulfolithocholic acid (SLCA). The study demonstrated that SLCA administration in feed at doses of 200 and 400 mg/kg for 35 days promoted a dose-dependent restoration of the bile acid ratio, reduced the share of hydrophobic deoxycholic acid, and improved classical biochemical liver markers.</p>
			</abstract>
			<kwd-group>
				<kwd>loach</kwd>
				<kwd> bile acids</kwd>
				<kwd> bile acid pool</kwd>
				<kwd> sulfolithocholic acid</kwd>
				<kwd> lithocholic acid sulfate</kwd>
				<kwd> hepatic steatosis</kwd>
				<kwd> toxic hepatopathy</kwd>
			</kwd-group>
		</article-meta>
	</front>
	<body>
		<sec>
			<title>HTML-content</title>
			<p>1. Introduction</p>
			<p>In recent decades, aquaculture has faced a serious challenge: the widespread occurrence of metabolic liver diseases in fish. The transition to high-protein and high-fat feeds, partial replacement of fishmeal with plant components, and deterioration of the ecological state of water bodies create prerequisites for hepatic steatosis and toxic hepatopathies </p>
			<p>[1][8][9][1][9]</p>
			<p>Bile acids are synthesized exclusively in hepatocytes from cholesterol. They perform not only an emulsifying function in the intestine but also act as signaling molecules regulating lipid and glucose homeostasis through activation of nuclear receptor FXR and membrane receptor TGR5 </p>
			<p>[1][3][5][3][5][8]</p>
			<p>Traditional approaches to the correction of hepatopathies in fish include diet therapy, plant-derived hepatoprotectors, and antioxidants </p>
			<p>[5][6][7][2][3][4][7][4][8]</p>
			<p>Exogenous bile acids administered with feed can not only compensate for the deficiency of endogenous bile acids but also modulate the activity of lipogenesis and β-oxidation enzymes through FXR activation. In addition, they influence the composition of intestinal microbiota, which indirectly affects secondary bile acid metabolism and the general state of the hepatobiliary system </p>
			<p>[9][10][11][1][3][11]</p>
			<p>Loaches are a convenient model object for studying these issues due to their relative hardiness, availability, and similarity of metabolic pathways with other commercial cyprinids. Unlike zebrafish, which are widely used in laboratory studies, loaches have larger sizes, allowing repeated blood sampling without lethal outcome and obtaining sufficient serum volumes for detailed biochemical analysis </p>
			<p>[8][10][11]</p>
			<p>The aim of this study was to evaluate the effectiveness of exogenous sulfolithocholic acid for correcting the bile acid pool shift in loaches with experimentally induced hepatobiliary pathologies. The following tasks were implemented: modeling hepatic steatosis and toxic liver damage using a high-fat diet and lead acetate solution; determination of the initial bile acid pool and classical biochemical liver markers; assessment of the dynamics of bile acid pool recovery during SLCA administration at different doses; and comparative analysis of the effectiveness of the studied doses </p>
			<p>[12][13][14][15]</p>
			<p>2. Research methods and principles</p>
			<p>Sexually mature common loaches (</p>
			<p>[12][13][14][15]</p>
			<p>Hepatic steatosis was modeled by transferring fish to a high-fat diet for 28 days. For this purpose, the standard feed was enriched with a mixture of sunflower and linseed oils in a 1:1 ratio to a final fat content of 20%. The control group (n = 18) continued to receive the standard diet. Toxic liver damage was modeled by adding lead acetate to the aquatic environment at a concentration of 0.4 mg/L calculated as metal ion for 96 hours. The choice of lead was due to its wide occurrence in anthropogenically polluted water bodies and proven hepatotoxicity accompanied by oxidative stress </p>
			<p>[8][12]</p>
			<p>For correction of the identified disorders, chemically pure sodium sulfolithocholate (Sigma-Aldrich, USA) was used. Fish with hepatic steatosis were divided into four groups (n = 14 each): untreated steatosis group (HS), group with SLCA added at 200 mg/kg feed (HS+SLCA-200), and group with SLCA added at 400 mg/kg feed (HS+SLCA-400). A similar division was performed for the groups with toxic damage: toxic hepatopathy without correction (TH), TH+SLCA-200, and TH+SLCA-400. The choice of doses was based on literature data on the tolerability and bioavailability of sulfated bile acids in fish </p>
			<p>[1][4][8][12][13][14][15]</p>
			<p>Classical biochemical parameters were determined on a semi-automatic biochemical analyzer SINNOWA BS-3000M (China). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined by a kinetic method using NADH. Alkaline phosphatase (ALP) activity was measured by a colorimetric method with p-nitrophenyl phosphate. Total bilirubin (TBil) was determined by the diazotized sulfanilic acid method. Triglycerides (TG) and total cholesterol (TC) were measured by enzymatic colorimetric methods. Total protein concentration was determined by the biuret method </p>
			<p>[12][13][14][15]</p>
			<p>The concentration of total bile acids (TBA) and individual fractions was determined by an enzymatic method using 3α-hydroxysteroid dehydrogenase. Fraction separation was performed by high-performance liquid chromatography followed by enzymatic detection. The sensitivity of the method was 0.4 µmol/L, and the coefficient of variation was no more than 3.8% </p>
			<p>[1][8]</p>
			<p>Statistical processing was performed using SPSS 27.0. Normality of distribution was checked by the Shapiro-Wilk test. One-way analysis of variance (ANOVA) with Tukey post hoc test was used to compare several groups. Differences were considered statistically significant at p &lt; 0.05. Data are presented as arithmetic mean ± standard deviation (M ± SD) </p>
			<p>[12][13][14][15]</p>
			<p>3. Main results</p>
			<p>Modeling of pathological states was accompanied by changes in both classical biochemical parameters and the bile acid pool. In the group with induced hepatic steatosis, by the 28th day of the high-fat diet, an increase in triglyceride level from 1.4 ± 0.3 to 3.2 ± 0.5 mmol/L (p &lt; 0.001) and total cholesterol from 3.1 ± 0.4 to 5.0 ± 0.6 mmol/L (p &lt; 0.001) was observed. ALT activity increased 1.7-fold, and AST activity increased 1.4-fold compared with the control. In the group with induced toxic hepatitis, the changes were more pronounced: ALT activity increased 2.1-fold, AST increased 1.9-fold, and total bilirubin increased from 2.4 ± 0.5 to 5.6 ± 0.9 µmol/L (p &lt; 0.001), indicating a cholestatic component </p>
			<p>[1][5][8]</p>
			<p>The initial bile acid pool in clinically healthy loaches was characterized by predominance of cholic acid over chenodeoxycholic acid, with a CA/CDCA ratio of 1.53 ± 0.14. The total bile acid level in blood serum was 5.1 ± 0.9 µmol/L. In hepatic steatosis, an increase in total bile acids to 13.7 ± 1.8 µmol/L (p &lt; 0.001) and a decrease in the CA/CDCA ratio to 0.76 ± 0.08 were observed. In induced toxic hepatitis, the total bile acid level reached 20.6 ± 2.4 µmol/L, and the CA/CDCA ratio decreased to 0.60 ± 0.07. A tendency toward an increase in deoxycholic acid, a secondary metabolite formed under the action of intestinal microbiota, was also noted. This indicates a violation of enterohepatic circulation of bile acids and enhanced bacterial transformation of primary bile acids </p>
			<p>[8][10][11]</p>
			<p>Administration of exogenous sulfolithocholic acid in feed led to pronounced positive dynamics in both experimental groups. Table 1 presents bile acid pool parameters on the 35th day of the experiment.</p>
			<table-wrap id="T1">
				<label>Table 1</label>
				<caption>
					<p> Bile acid pool of loach blood serum after 35 days of pharmacocorrection</p>
				</caption>
				<table>
					<tr>
						<td>Group</td>
						<td>TBA</td>
						<td>CA</td>
						<td>CDCA</td>
						<td>DCA</td>
						<td>CA/CDCA</td>
					</tr>
					<tr>
						<td>Control</td>
						<td>5.1 ± 0.9</td>
						<td>2.6 ± 0.4</td>
						<td>1.7 ± 0.3</td>
						<td>0.5 ± 0.1</td>
						<td>1.53</td>
					</tr>
					<tr>
						<td>HS (without correction)</td>
						<td>13.7 ± 1.8*</td>
						<td>4.5 ± 0.7*</td>
						<td>5.9 ± 0.9*</td>
						<td>2.9 ± 0.6*</td>
						<td>0.76*</td>
					</tr>
					<tr>
						<td>HS+SLCA-200</td>
						<td>9.2 ± 1.2*#</td>
						<td>3.6 ± 0.5*#</td>
						<td>3.8 ± 0.6*#</td>
						<td>1.5 ± 0.4*#</td>
						<td>0.95#</td>
					</tr>
					<tr>
						<td>HS+SLCA-400</td>
						<td>7.4 ± 1.0#</td>
						<td>3.3 ± 0.5#</td>
						<td>2.9 ± 0.5#</td>
						<td>1.0 ± 0.3#</td>
						<td>1.14#</td>
					</tr>
					<tr>
						<td>TH (without correction)</td>
						<td>20.6 ± 2.4*</td>
						<td>5.6 ± 0.8*</td>
						<td>9.4 ± 1.2*</td>
						<td>5.1 ± 0.9*</td>
						<td>0.60*</td>
					</tr>
					<tr>
						<td>TH+SLCA-200</td>
						<td>12.4 ± 1.6*#</td>
						<td>4.4 ± 0.6*#</td>
						<td>5.1 ± 0.8*#</td>
						<td>2.2 ± 0.5*#</td>
						<td>0.86#</td>
					</tr>
					<tr>
						<td>TH+SLCA-400</td>
						<td>9.8 ± 1.3#</td>
						<td>4.0 ± 0.6#</td>
						<td>3.9 ± 0.6#</td>
						<td>1.6 ± 0.4#</td>
						<td>1.03#</td>
					</tr>
				</table>
			</table-wrap>
			<p>Analysis of the data allows the conclusion that SLCA at a dose of 200 mg/kg effectively reduces the level of total bile acids and shifts the CA/CDCA ratio toward physiological values. However, a more pronounced effect was observed with SLCA at 400 mg/kg. In this group, the parameters were closest to the control values, especially in modeling hepatic steatosis. It was noted that in the group with toxic hepatitis, restoration of the bile acid pool was slower; on the 35th day of pharmacocorrection, the CA/CDCA ratio did not completely reach the control values </p>
			<p>[1][3][8]</p>
			<p>The dynamics of classical biochemical parameters during pharmacocorrection are presented in Table 2.</p>
			<table-wrap id="T2">
				<label>Table 2</label>
				<caption>
					<p>Biochemical parameters of loach blood serum on the 35th day of pharmacocorrection</p>
				</caption>
				<table>
					<tr>
						<td>Group</td>
						<td>ALT, U/L</td>
						<td>AST, U/L</td>
						<td>ALP, U/L</td>
						<td>TBil, μmol/L</td>
						<td>TG, mmol/L</td>
						<td>TC, mmol/L</td>
					</tr>
					<tr>
						<td>Control</td>
						<td>21.5 ± 3.6</td>
						<td>35.2 ± 5.1</td>
						<td>24.8 ± 3.9</td>
						<td>2.4 ± 0.5</td>
						<td>1.4 ± 0.3</td>
						<td>3.1 ± 0.4</td>
					</tr>
					<tr>
						<td>HS (without correction)</td>
						<td>36.9 ± 5.4*</td>
						<td>49.8 ± 6.2*</td>
						<td>31.2 ± 4.7*</td>
						<td>3.3 ± 0.6*</td>
						<td>3.2 ± 0.5*</td>
						<td>5.0 ± 0.6*</td>
					</tr>
					<tr>
						<td>HS+SLCA-200</td>
						<td>30.4 ± 4.6*#</td>
						<td>43.5 ± 5.7*#</td>
						<td>28.6 ± 4.3*#</td>
						<td>2.9 ± 0.5#</td>
						<td>2.5 ± 0.4*#</td>
						<td>4.1 ± 0.5*#</td>
					</tr>
					<tr>
						<td>HS+SLCA-400</td>
						<td>25.7 ± 4.0#</td>
						<td>38.9 ± 5.2#</td>
						<td>26.1 ± 4.0#</td>
						<td>2.6 ± 0.5#</td>
						<td>1.9 ± 0.3#</td>
						<td>3.4 ± 0.4#</td>
					</tr>
					<tr>
						<td>TH (without correction)</td>
						<td>44.8 ± 6.1*</td>
						<td>68.4 ± 8.0*</td>
						<td>40.2 ± 5.9*</td>
						<td>5.6 ± 0.9*</td>
						<td>2.2 ± 0.4*</td>
						<td>4.0 ± 0.5*</td>
					</tr>
					<tr>
						<td>TH+SLCA-200</td>
						<td>36.5 ± 5.2*#</td>
						<td>56.7 ± 7.1*#</td>
						<td>34.8 ± 5.2*#</td>
						<td>4.2 ± 0.7*#</td>
						<td>1.8 ± 0.3#</td>
						<td>3.5 ± 0.5#</td>
					</tr>
					<tr>
						<td>TH+SLCA-400</td>
						<td>29.9 ± 4.5#</td>
						<td>46.2 ± 6.0#</td>
						<td>29.7 ± 4.5#</td>
						<td>3.2 ± 0.6#</td>
						<td>1.5 ± 0.3#</td>
						<td>3.1 ± 0.4#</td>
					</tr>
				</table>
			</table-wrap>
			<p>The most indicative dynamics in the context of this study was the activity of transaminases and alkaline phosphatase. In the group with modeled hepatic steatosis receiving SLCA at 400 mg/kg, ALT activity decreased by 30.3% from the initial level (from 36.9 to 25.7 U/L), AST by 21.9%, and ALP by 16.3%. In the group with toxic liver damage, the effect was less pronounced: ALT decreased by 33.3%, AST by 32.5%, and ALP by 26.1%. The triglyceride level in the HS+SLCA-400 group approached the control values (1.9 ± 0.3 mmol/L versus 1.4 ± 0.3 in the control), which confirms the ability of exogenous sulfated bile acid to restore some links of lipid metabolism </p>
			<p>[1][3][5]</p>
			<p>It was noted that in all experimental groups with pharmacocorrection, a decrease in the level of deoxycholic acid, a secondary metabolite with pronounced hydrophobic and cytotoxic properties, was observed. The most pronounced decrease in DCA (from 2.9 to 1.0 µmol/L in the HS+SLCA-400 group and from 5.1 to 1.6 µmol/L in the TH+SLCA-400 group) indicates restoration of enterohepatic circulation of bile acids and reduction of bacterial transformation of primary bile acids </p>
			<p>[8][10][11]</p>
			<p>Comparative analysis of the effectiveness of SLCA doses revealed certain differences. In hepatic steatosis, the 200 mg/kg dose was moderately effective, but SLCA at 400 mg/kg more markedly restored the CA/CDCA ratio and reduced transaminase levels. In toxic liver damage, the difference between doses was more pronounced: SLCA at 400 mg/kg demonstrated a more significant hepatoprotective effect. This may be due to the fact that sulfolithocholic acid, due to its sulfated structure, is more hydrophilic, less cytotoxic, and capable of competing with hydrophobic bile acids for intestinal and hepatic transporters. It promotes displacement of hydrophobic fractions from the pool, reduces their damaging effect on hepatocyte membranes, and modulates FXR-dependent signaling </p>
			<p>[1][3][5][11]</p>
			<p>Correlation analysis revealed a close relationship between restoration of the bile acid ratio and normalization of biochemical parameters. The correlation coefficient between the CA/CDCA ratio and ALT activity was r = –0.81 (p &lt; 0.01), between CA/CDCA and ALP r = –0.76 (p &lt; 0.01), and between CA/CDCA and triglyceride level r = –0.71 (p &lt; 0.01). This confirms that the bile acid pool is not merely a concomitant predictor but also an active link in the pathogenetic process, and its pharmacocorrection naturally leads to improvement of the functional state of the liver </p>
			<p>[1][8][14]</p>
			<p>4. Conclusion</p>
			<p>The conducted study confirmed that exogenous sulfolithocholic acid is an effective means of correcting the bile acid pool shift in loaches with experimentally induced hepatobiliary pathologies. Both hepatic steatosis induced by a high-fat diet and toxic hepatitis caused by lead acetate led to changes in the bile acid ratio: an increase in the level of total bile acids, a decrease in the ratio of cholic acid to chenodeoxycholic acid, and accumulation of hydrophobic deoxycholic acid. Administration of sulfolithocholic acid at doses of 200 and 400 mg/kg feed provided a reliable restoration of the bile acid ratio, with the most pronounced effect observed at 400 mg/kg </p>
			<p>[1][8]</p>
			<p>It was established that correction of the bile acid pool is accompanied by restoration of classical biochemical predictors of liver damage: a decrease in the activity of transaminases, alkaline phosphatase, bilirubin, triglycerides, and total cholesterol. The closest correlations were found between the CA/CDCA ratio and ALT activity (r = –0.81), which allows this parameter to be considered an integral indicator of pharmacotherapy effectiveness. Sulfolithocholic acid can be considered a promising agent for further study in aquaculture as a modulator of bile acid homeostasis and hepatoprotection </p>
			<p>[1][8][14]</p>
		</sec>
		<sec sec-type="supplementary-material">
			<title>Additional File</title>
			<p>The additional file for this article can be found as follows:</p>
			<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="S1" xlink:href="https://doi.org/10.5334/cpsy.78.s1">
				<!--[<inline-supplementary-material xlink:title="local_file" xlink:href="https://research-journal.org/media/articles/27919.docx">27919.docx</inline-supplementary-material>]-->
				<!--[<inline-supplementary-material xlink:title="local_file" xlink:href="https://research-journal.org/media/articles/27919.pdf">27919.pdf</inline-supplementary-material>]-->
				<label>Online Supplementary Material</label>
				<caption>
					<p>
						Further description of analytic pipeline and patient demographic information. DOI:
						<italic>
							<uri>https://doi.org/10.60797/IRJ.2026.173.63</uri>
						</italic>
					</p>
				</caption>
			</supplementary-material>
		</sec>
	</body>
	<back>
		<ack>
			<title>Acknowledgements</title>
			<p/>
		</ack>
		<sec>
			<title>Competing Interests</title>
			<p/>
		</sec>
		<ref-list>
			<ref id="B1">
				<label>1</label>
				<mixed-citation publication-type="confproc">Popova O.S. Metabolizm zhirnyh kislot u ryb [Features of bile acid metabolism in fish] / O.S. Popova, L.A. Agafonova // Mezhdunarodnyj veterinarnyj vestnik [International Veterinary Bulletin]. — 2022. — № 1. — P. 61–65. — DOI: 10.52419/issn2072-2419.2022.1.61.</mixed-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation publication-type="confproc">Isanbaeva A.R. Ocenka terapevticheskoj effektivnosti razlichnyh preparatov ursodezoksiholevoj kisloty pri lechenii biliarnogo sladzha [Evaluation of therapeutic efficiency of various drugs of ursodeoxycholic acid in the treatment of biliary sludge] / A.R. Isanbaeva, G.M. Sakhautdinova // Terapevticheskij arhiv [Therapeutic Archive]. — 2021. — Vol. 93. — № 12. — P. 1477–1481. — DOI: 10.26442/00403660.2021.12.201250.</mixed-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation publication-type="confproc">Absandze K.G. Lechenie pervichnogo biliarnogo holangita ursodezoksiholevoj kislotoj [Primary biliary cholangitis and incomplete response to therapy with ursodeoxycholic acid: who is to blame and what to do?] / K.G. Absandze, E.V. Vinnitskaya, Yu.G. Sandler [et al.] // Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. — 2022. — Vol. 18. — № 22. — P. 14–19. — DOI: 10.33978/2307-3586-2022-18-22-14-18.</mixed-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation publication-type="confproc"> Popova O.S. Vyzhivanie ryb v kisloj srede pod vozdejstviem ursodezoksiholevoj kisloty [Assessment of fish survival in an acidic environment under the influence of ursodeoxycholic acid] / O.S. Popova, V.S. Ponamarev // Mezhdunarodnyj veterinarnyj vestnik [International Veterinary Bulletin]. — 2022. — № 4. — P. 159–164. — DOI: 10.52419/issn2072-2419.2022.4.159.</mixed-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation publication-type="confproc">Kardash E.V. Obzor mekhanizmov dejstviya i svojstv gepatoprotektornyh preparatov [Review of the mechanisms of action and properties of hepatoprotective drugs] / E.V. Kardash, E.M. Grigorieva, A.G. Yemelyanova [et al.] // Patogenez [Pathogenesis]. — 2020. — Vol. 18. — № 2. — S. 36–44. — DOI: 10.25557/2310-0435.2020.02.36-44.</mixed-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation publication-type="confproc">Saparmammedova G. Gepatoprotektory: kriticheskij analiz mekhanizmov dejstviya i ih mesto v klinicheskoj praktike [Hepatoprotectors: a critical analysis of the mechanisms of action and their place in clinical practice] / G. Saparmammedova // Novaya nauka: ot idei k rezul'tatu [New science: from idea to result]. — 2025. — № 12. — P. 185–188.</mixed-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation publication-type="confproc"> Skvortsova E.M. Osobennosti primeneniya zhelchegonnyh preparatov i mekhanizmy ih dejstviya [Features of the use of cholagogue medications and the mechanisms of their action] / E.M. Skvortsova, V.V. Skvortsov, I.Ya. Ismailov [et al.] // Terapevt [Therapist], 2018. — № 3. — P. 10–16.</mixed-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation publication-type="confproc">Prusakov A.V. Rol' organicheskih kislot v pitanii ryb: ot diagnosticheskogo priznaka k razrabotke strategij farmakokorrekcii [Imbalance of bile acids in fish under environmental stress: from a diagnostic sign to the development of pharmacocorrection strategies] / A.V. Prusakov, V.S. Ponamarev // Mezhdunarodnyj nauchno-issledovatel'skij zhurnal [International Scientific Research Journal]. — 2025. — № 10 (160). — DOI: 10.60797/IRJ.2025.160.78.</mixed-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation publication-type="confproc">Alieva E.M. Lechebno-profilakticheskie meropriyatiya v rybovodstve [Therapeutic and preventive measures in fish farming] / E.M. Alieva, M.M. Alieva, Z.S. Mirzakhanova // Sovremennye problemy i perspektivy agropromyshlennogo kompleksa Respubliki Dagestan [Modern Problems and Prospects of the Agro‑Industrial Complex of the Republic of Dagestan] : materials of the Regional Scientific Conference dedicated to the Year of Science and Technology. — Makhachkala : Dagestan State Agrarian University named after M.M. Dzhambulatov, 2021. P. 118–126.</mixed-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation publication-type="confproc">Belcheva N.N. Obychnaya i sinhronnaya spektrofluorimetriya zhelchi ryby kak pokazatel' zagryazneniya morskoj sredy policiklicheskimi aromaticheskimi uglevodorodami [Fixed wavelength and synchronous fluorescence of fish bile as a monitoring tool for polyaromatic hydrocarbon marine pollution] / N.N. Belcheva, A.A. Istomina // Morskie biologicheskie issledovaniya: dostizheniya i perspektivy [Marine biological research: achievements and prospects] : collection of materials All-Russian Scientific and Practical Conference with international participation dedicated to the 145th anniversary of the Sevastopol Biological Station : in 3 volumes. — Sevastopol : EKOSI‑Hydrophysics, 2016. — Vol. 3. — P. 39–42.</mixed-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation publication-type="confproc"> Belcheva N.N. Nalichie policiklicheskih aromaticheskih uglevodorodov (PCA) v ryb'ej zhelchi vazhno dlya sravnitel'noj ocenki zagryazneniya pribrezhnyh vod [Determination of metabolites of polycyclic aromatic hydrocarbons in fish bile for a comparative assessment of pollution of coastal waters] / N.N. Belcheva, A.A. Istomina, A.Yu. Zvyagintsev [et al.] // Voprosy ikhtiologii [Questions of Ichthyology]. — 2017. — Vol. 57. — № 6. — P. 737–742. — DOI: 10.7868/S0042875217050034.</mixed-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation publication-type="confproc"> Zavodovsky B.V. Klinicheskaya biohimiya [Clinical biochemistry] : manual / B.V. Zavodovsky, E.A. Zagorodneva, N.G. Krayushkina [et al.]. — Volgograd : Volgograd State Medical University, 2023. — 164 p.</mixed-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation publication-type="confproc">Malinovskaya N.A. Biohimiya i patobiohimiya lipidnogo obmena [Biochemistry and pathobiochemistry of lipid metabolism] : educational and methodical manual / N.A. Malinovskaya, L.V. Trufanova, G.E. Herzog [et al.]. — Krasnoyarsk : Krasnoyarsk State Medical University, 2024. — 71 p.</mixed-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation publication-type="confproc"> Belozertseva N.S. Veterinarnaya klinicheskaya biohimiya pecheni [Veterinary Clinical Biochemistry of the Liver] : lecture / N.S. Belozertseva, Yu.S. Kruglova, Zh.Yu. Muradyan. — Moscow : FSBEI HE MGAVMiB‑MVA named after K.I. Skryabin, 2024. — 36 p.</mixed-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation publication-type="confproc"> Karpenko E.N. Biohimiya [Biochemistry] : practical course for students / E.N. Karpenko, S.V. Kuznetsov, N.F. Bashirova. — Bryansk : Novyj proekt, 2024. — 136 p.</mixed-citation>
			</ref>
		</ref-list>
	</back>
	<fundings>
		<funding lang="RUS">Исследование выполнено при поддержке гранта Российского научного фонда № 25-26-00274, https://rscf.ru/project/25-26-00274/.</funding>
		<funding lang="ENG">The study was supported by the Russian Science Foundation grant № 25-26-00274, https://rscf.ru/project/25-26-00274/.</funding>
	</fundings>
</article>